Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Cell Transplant. 2022 Jan-Dec;31:9636897221090259. doi: 10.1177/09636897221090259.
The pandemic of coronavirus disease 2019 (COVID-19) continuously causes deaths worldwide, representing a considerable challenge to health care and economic systems with a new precedent in human history. Many therapeutic medicines primarily focused on preventing severe organ damage and complications, which can be fatal in some confirmed cases. The synthesized modified mRNA (modRNA) represents a nonviral, integration-free, zero-footprint, efficient, and safe strategy for vaccine discovery. modRNA-based technology has facilitated the rapid development of the first COVID-19 vaccines due to its cost- and time-saving properties, thus initiating a new era of prophylactic vaccines against infectious diseases. Recently, COVID-19 modRNA vaccines were approved, and a large-scale vaccination campaign began worldwide. To date, results suggest that the modRNA vaccines are highly effective against virus infection, which causes COVID-19. Although short-term studies have reported that their safety is acceptable, long-term safety and protective immunity remain unclear. In this review, we describe two major approved modRNA vaccines and discuss their potential myocarditis complications.
2019 年冠状病毒病（COVID-19）大流行持续在全球范围内造成死亡，这对医疗保健和经济系统构成了重大挑战，在人类历史上开创了一个新的先例。许多治疗药物主要侧重于预防严重的器官损伤和并发症，这些损伤和并发症在一些确诊病例中可能是致命的。合成修饰信使 RNA（modRNA）是一种非病毒、无整合、零痕迹、高效和安全的疫苗发现策略。由于其具有节省成本和时间的特性，基于 modRNA 的技术促进了第一批 COVID-19 疫苗的快速开发，从而开创了预防传染病的预防性疫苗的新时代。最近，COVID-19 modRNA 疫苗获得批准，全球范围内开始了大规模的疫苗接种运动。迄今为止，结果表明，modRNA 疫苗对导致 COVID-19 的病毒感染具有高度有效性。尽管短期研究报告称其安全性可以接受，但长期安全性和保护免疫仍不清楚。在这篇综述中，我们描述了两种主要批准的 modRNA 疫苗，并讨论了它们可能引发的心肌炎并发症。
